In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

While Wall Street analysts remain cautious on Hims & Hers Health (HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...